Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 2/2015

01.02.2015 | Current Opinion

Role of Apomorphine in the Treatment of Parkinson’s Disease

verfasst von: Allison Boyle, William Ondo

Erschienen in: CNS Drugs | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Current research shows that apomorphine is an effective treatment for symptoms of Parkinson’s Disease (PD). The highly lipophilic structure allows apomorphine to cross cell membranes rapidly, leading to the rapid onset of action for on/off symptoms of PD. The use of apomorphine was limited in the past due to peripheral side effects, but with the advent of better delivery systems and medications to control side effects, apomorphine is better tolerated and more widely in use. The major delivery systems are continuous subcutaneous infusions and intermittent subcutaneous injections, but other delivery routes are under investigation. The purpose of this article is to discuss the current use of apomorphine, the current delivery systems and to discuss future research.
Literatur
1.
Hagell P, Odin P, Shing M. Apomorphine in Parkinson’s disease. UNI-MED-Verlag, 2008.
2.
Gessa GL, Corsini GU. Apomorphine and other dopaminomimetics: basic pharmacology. New York: Raven Press (ID); 1981.
3.
Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(2):85–92.CrossRefPubMed
4.
Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson’s disease. Biomed Pharmacother Biomed Pharmacother. 1995;49(4):197–209.CrossRef
5.
6.
Ribaric S. The pharmacological properties and therapeutic use of apomorphine. Molecules. 2012;17(5):5289–309.CrossRefPubMed
7.
Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709–16.CrossRefPubMedCentralPubMed
8.
Lucotti A, Tommasini M, Casella M, Morganti A, Gramatica F, Zerbi G. TLC—surface enhanced Raman scattering of apomorphine in human plasma. Vib Spectrosc. 2012;62:286–91.CrossRef
9.
LeWitt PA, Ondo WG, Van Lunen B, Bottini PB. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009;32(2):89–93.CrossRefPubMed
10.
Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol. 2011;69(2):248–56.CrossRefPubMed
11.
Gassen M, Gross A, Youdim MBH. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord. 1998;13(4):661–7.
12.
Gassen M, Glinka Y, Pinchasi B, et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Clin Pharmacol. 1996;308:219–26.CrossRef
13.
Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord Off J Mov Disord Soc. 1991;6(3):212–6.CrossRef
14.
Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6(6):429–53.CrossRefPubMed
15.
Holford NG, Sheiner L. Understanding the dose–effect relationship. Clin Pharmacokinet. 1981;6(6):429–53.CrossRefPubMed
16.
Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson’s disease. Parkinsonism Relat Disord. 2000;6(4):237–40.CrossRefPubMed
17.
Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251–3.PubMed
18.
Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M. Treatment of Parkinson’s disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976;294(11):567–72.CrossRefPubMed
19.
20.
Barker R, Duncan J, Lees A. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1989;1(8639):675.CrossRefPubMed
21.
Oertel, Wolfgang H, et al. Apomorphine test for dopaminergic responsiveness. Lancet. 1989;333(8649):1262–3.
22.
Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990;336(8706):32–4.CrossRefPubMed
23.
24.
Factor SA. Literature review intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology. 2004;62(6 suppl 4):S12–7.CrossRefPubMed
25.
Steiger MJ, Quinn NP, Marsden CD. The clinical use of apomorphine in Parkinson’s disease. J Neurol. 1992;239(7):389–93.PubMed
26.
Bowron A. Practical considerations in the use of apomorphine injectable. Neurology. 2004;62(6 suppl 4):S32–6.CrossRefPubMed
27.
Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on–off oscillations. Lancet. 1988;1(8582):403–6.CrossRefPubMed
28.
Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. Subcutaneous apomorphine in Parkinson’s disease. Lancet. 1988;1(8591):943.CrossRefPubMed
29.
Chaudhuri KR, Critchley P, Abbott RJ, Pye IF, Millac PA. Subcutaneous apomorphine for on–off oscillations in Parkinson’s disease. Lancet. 1988;2(8622):1260.CrossRefPubMed
30.
Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson’s disease. Revue Neurol. 1990;146(2):116–22.
31.
Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1990;53(2):96–101.CrossRefPubMedCentralPubMed
32.
Petit H, Vermersch P, Caparros-Lefebvre D. Subcutaneous apomorphine in major motor oscillations of parkinsonian patients. Presse Med. 1992;21(4):172.PubMed
33.
Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees AJ, Stern GM, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet. 1988;2(8626–8627):1451–3.CrossRefPubMed
34.
Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(10):728–41.CrossRefPubMed
35.
Stacy M, Spears J, Van Lunen B. Implications of Motor fluctuations in Parkinson’s patients on Chronic Therapy (IMPACT) registry: comparison of patient and physician reported data. Mov Disord. 2006;21(Supplement 13):1.
36.
Montastruc JL, Rascol O, Senard JM, Gualano V, Bagheri H, Houin G, et al. Sublingual apomorphine in Parkinson’s disease: a clinical and pharmacokinetic study. Clin Neuropharmacol. 1991;14(5):432–7.CrossRefPubMed
37.
Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58(9):1385–92.CrossRefPubMed
38.
Hauser RA, Isaacson S, Clinch T. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014;20(11):1171–6.
39.
Anthony Giovinazzo M, Dir C, CEO CT, Agro IA, Bryson N, Tankosic IT. Apomorphine for off periods in Parkinson’s disease: clinical use and potential of a developmental sublingual formulation, APL130277. In: Conference M, editor. 2013.
40.
Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH, Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(2):93–100.CrossRefPubMed
41.
Isaacson S, Ondo W, Pagan F. Apomorphine improves morning akinesia in Parkinson’s disease: interim analysis of the AM-IMPAKT trial. European Journal of Neurology; 2014: Wiley-Blackwell 111 River St, Hoboken 07030–5774, NJ USA; 2014. p. 68.
42.
Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro Garcia A, Alonso Frech F, Alvarez Lopez M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord Off J Mov Disord Soc. 2008;23(8):1130–6.CrossRef
43.
Todorova A, Chaudhuri KR. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(12):1073–8.
44.
Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord Off J Mov Disord Soc. 2002;17(6):1235–41.CrossRef
45.
Manson A, Hanagasi H, Turner K, Patsalos P, Carey P, Ratnaraj N, et al. Intravenous apomorphine therapy in Parkinson’s disease clinical and pharmacokinetic observations. Brain J Neurol. 2001;124(2):331–40.CrossRef
46.
Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26(2):232–8.CrossRefPubMed
47.
LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(6 Suppl 4):S8–11.CrossRefPubMed
48.
Garrido JMPJ, Delerue-Matos C, Borges F, Macedo TRA, Oliveira-Brett AM. New insights into the oxidation pathways of apomorphine. J Chem Soc Perkin Trans 2. 2002;10:1713–7.CrossRef
49.
Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 1999;14(4):664–8.CrossRef
50.
Morgan FG, Main MJ. Compositions and uses. Google Patents; 2013.
51.
Bartus RT, Emerich DF. Pulmonary delivery in treating disorders of the central nervous system. Google Patents; 2003.
52.
Tribl GG, Sycha T, Kotzailias N, Zeitlhofer J, Auff E. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry. 2005;76(2):181–5.CrossRefPubMedCentralPubMed
53.
Fridman EA, Krimchansky BZ, Bonetto M, Galperin T, Gamzu ER, Leiguarda RC, et al. Continuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj. 2010;24(4):636–41.CrossRefPubMed
54.
Pistoia F, Mura E, Govoni S, Fini M, Sarà M. Awakenings and awareness recovery in disorders of consciousness. CNS Drugs. 2010;24(8):625–38.CrossRefPubMed
Metadaten
Titel
Role of Apomorphine in the Treatment of Parkinson’s Disease
verfasst von
Allison Boyle
William Ondo
Publikationsdatum
01.02.2015
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 2/2015
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-014-0221-z

Weitere Artikel der Ausgabe 2/2015

CNS Drugs 2/2015 Zur Ausgabe

Adis Drug Evaluation

Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis

Systematic Review

Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms

Therapy in Practice

Seizure Associated with Clozapine: Incidence, Etiology, and Management

Short Communication

Weight Regain after Discontinuation of Topiramate Treatment in Patients with Migraine: a Prospective Observational Study

Leading Article

mTOR Inhibition in Epilepsy: Rationale and Clinical Perspectives

Review Article

The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise